Phase II randomized study of radiotherapy and three-year androgen deprivation with or without concurrent weekly docetaxel in high-risk localized prostate cancer patients.

Joan Carles,Enrique Gallardo,Montserrat Doménech,Albert Font,Joaquim Bellmunt,Mariona Figols,Begoña Mellado,María Isabel Sáez,Cristina Suárez,María José Méndez,Pablo Maroto,Raquel Luque, Teresa de Portugal,Ramón Aldabo,Teresa Bonfill,Rafael Morales-Barrera, José García,Sonia Maciá,Xavier Maldonado,Palmira Foro

International Journal of Radiation Oncology*Biology*Physics（2019）

引用 4|浏览46

暂无评分

摘要

Concurrent weekly docetaxel can be administered safely with standard doses of radiotherapy without a significant increase in the toxicity profile. No statistically significant differences for 5-year biochemical RFS, PFS and OS has been observed when docetaxel was added to conventional treatment.

查看译文

关键词

biochemical relapse,docetaxel,high-risk localized prostate cancer,radiotherapy

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要